Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates

Antibody-drug conjugates (ADCs) are promising therapies for haematological cancers. Historically, their therapeutic benefit is due to ADC targeting of lineage-restricted antigens. The C-X-C motif chemokine receptor 4 (CXCR4) is attractive for targeted therapy of haematological cancers, given its exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Maria José, Kudaravalli, Jyothirmayee, Ma, Jing-Tyan, Ho, Wei-Hsien, Delaria, Kathy, Holz, Charles, Stauffer, Angela, Chunyk, Allison Given, Zong, Qing, Blasi, Eileen, Buetow, Bernard, Tran, Thomas-Toan, Lindquist, Kevin, Dorywalska, Magdalena, Rajpal, Arvind, Shelton, David L., Strop, Pavel, Liu, Shu-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384886/
https://www.ncbi.nlm.nih.gov/pubmed/30792442
http://dx.doi.org/10.1038/s41598-019-38745-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384886/
https://www.ncbi.nlm.nih.gov/pubmed/30792442
http://dx.doi.org/10.1038/s41598-019-38745-x

Ejemplares similares